12 Hidden Gems from 2025: Stocks to Watch in the New Year
ByAinvest
Wednesday, Dec 31, 2025 11:35 am ET1min read
CDTX--
CELC--
NBTX--
PVLA--
Several lesser-known stocks that delivered significant returns in 2025 include Palvella Therapeutics (PVLA), Cidara Therapeutics (CDTX), Celcuity (CELC), and Nanobiotix (NBTX). PVLA's lead product, QTORIN rapamycin, saw a multi-billion-dollar opportunity if approved, while CDTX was acquired by Merck for $9.2 billion. CELC's Gedatolisib showed promise in breast and prostate cancer trials, and NBTXR3 demonstrated efficacy in head and neck squamous cell carcinoma.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet